Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease

Phase 3 Unknown 327 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.

Timeline

Start: 2019-02-07
Primary completion: 2020-02
Completion: 2020-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABEPRAZAN	Small molecule	—	Oral

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease

Summary

Timeline

Drugs

Indications